AKT1 and breast carcinoma: Studies by Sun et al. have shown that PDGFRβ can activate the PI3K/AKT pathway and promote breast cancer cell proliferation and survival [33,34], suggesting that Ezetimibe may inhibit TNBC growth by regulating the PDGFRβ/AKT signaling pathway.